B
Bull
Bull · 25%NOTV
$2.18
情景价格
$0.080
-0.013 (-15.89%)收盘时
Loading chart…
- High
- 0.098
- Open
- 0.085
- VWAP
- 0.09
- Vol
- 17.27M
- Mkt Cap
- 44.93M
- Low
- 0.080
- Amount
- 1.48M
- EV/EBITDA, TTM
- -14.11
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
估值指标
The current forward P/E ratio for Inotiv Inc (NOTV) is 3.72, compared to its 5-year average forward P/E of -0.47.
Alphio AI Price Scenarios for NOTV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
9.007-20NewsfilterInotiv Emerges from Chapter 11 with Stronger Balance Sheet
- 9.007-14Newsfilter
Inotiv Confirms Reorganization Plan, Strengthening Financial Structure
9.006-03seekingalphaInotiv Files for Chapter 11 Bankruptcy Protection
- 9.006-03Newsfilter
Inotiv Secures $65 Million Financing for Restructuring
9.003-18seekingalphaFDA Issues Draft Guidance on Alternatives to Animal Testing
NOTV FAQ — answered by Alphio AI
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。